Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 3/20 | 1.00 |
| ▸ | ADRA1A known ✓ | P35348 | 3/20 | 0.98 |
| ▸ | MEN1 | O00255 | 1/20 | 0.98 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30450204 | 0.99 | ADRA1A (1.00) | ADRA2AADRA1AMEN1ALOX15KMT2A | |
| SCHEMBL8856920 | 0.99 | ADRA1A (1.00) | ADRA2AADRA1AMEN1ALOX15KMT2A | |
| SCHEMBL8856947 | 0.84 | ADRA1A (0.74) | ADRA2AADRA1AMEN1ALOX15KMT2A | |
| SCHEMBL8241485 | 0.79 | ADRA1A (0.66) | ADRA2AADRA1AMEN1ALOX15KMT2A | |
| SCHEMBL768604 | 0.79 | ADRA1A (0.66) | ADRA2AADRA1AMEN1ALOX15KMT2A | |
| SCHEMBL10752562 | 0.76 | ADRA1A (0.62) | ADRA2AADRA1AMEN1ALOX15KMT2A | |
| SCHEMBL9814151 | 0.76 | ADRA1A (0.62) | ADRA2AADRA1AMEN1ALOX15KMT2A | |
| SCHEMBL9814108 | 0.76 | ADRA1A (0.63) | ADRA2AADRA1AMEN1ALOX15KMT2A | |
| SCHEMBL7097236 | 0.76 | ADRA2A (0.66) | ADRA2AADRA1AMEN1ALOX15KMT2A | |
| SCHEMBL9814117 | 0.76 | ADRA1A (0.62) | ADRA2AADRA1AMEN1ALOX15KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8778897-B2 | Method of treatment using α-1-adrenergic agonist compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-07-15 | — | — | US | claimed |
| US-8324178-B2 | Method of treatment using alpha-1-adrenergic agonist compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-12-04 | — | — | US | claimed |
| US-20200239398-A1 | METHYLENE-CYCLOALKYLACETATE DERIVATIVES AND THEIR USE IN TREATMENT OF NEUROTROPIC CONDITIONS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2020-07-30 | — | — | US | disclosed |
| US-9784726-B2 | Screening method, a kit, a method of treatment and a compound for use in a method of treatment | ATROGI AB (SE) | 2017-10-10 | — | — | US | disclosed |
| US-9364462-B2 | Alpha-1-adrenergic receptor agonist therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-06-14 | — | — | US | disclosed |
| US-20160003803-A1 | A SCREENING METHOD, A KIT, A METHOD OF TREATMENT AND A COMPOUND FOR USE IN A METHOD OF TREATMENT | ATROGI AB (SE) | 2016-01-07 | — | — | US | disclosed |
| WO-2014108449-A1 | A SCREENING METHOD, A KIT, A METHOD OF TREATMENT AND A COMPOUND FOR USE IN A METHOD OF TREATMENT | ATROGI AB (SE) | 2014-07-17 | — | — | WO | disclosed |
| US-8778897-B2 | Method of treatment using α-1-adrenergic agonist compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-07-15 | — | — | US | disclosed |
| US-20140121257-A1 | ALPHA-1-ADRENERGIC RECEPTOR AGONIST THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-05-01 | — | — | US | disclosed |
| US-20130040904-A1 | METHOD OF TREATMENT USING ALPHA-1-ADRENERGIC AGONIST COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-02-14 | — | — | US | disclosed |
| US-8324178-B2 | Method of treatment using alpha-1-adrenergic agonist compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100113377-A1 | Method of Treatment Using Alpha-1-Adrenergic Agonist Compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239398-A1 | METHYLENE-CYCLOALKYLACETATE DERIVATIVES AND THEIR USE IN TREATMENT OF NEUROTROPIC CONDITIONS | PMP22, NLN, CLN6 | ADRA2A 468/4885ADRA1A 1445/4885MEN1 1300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.